MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. These campaigns focus on dispelling myths, highlighting success stories, and educating the public about the science behind cannabis-based treatments.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Media Releases. Accessibility.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. Mitchell et al., Divito & Robert F. 11 × 11. TIMES (Nov. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

JUNE 24, 2021

Collins responded that they have made “some progress” but that the schedule 1 listing of the substances causes researchers to have to “overcome significant hurdles to access it”. . However, it is challenging to do this as the scheduling of substances stands in the way of accessing them- even if allocations have been made to do so. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Media Enquiries: Sam Brown Inc. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. As more people gain access to medical marijuana, dependence on opioids for pain relief is likely to decline. Marijuana Preferred Over Pain Pills. percent, respectively. million to 11.4

Marijuana 87

Marijuana Patients Clinical Trials Data 87

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 22, 2021

Medicines and Healthcare products Regulatory Agency (the “ MHRA ”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“ DMT ”) assisted therapies for the treatment of major depressive disorder (“ MDD ”). About Small Pharma.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

CannaMD

MARCH 8, 2021

1455 covers three major themes: medical marijuana advertising, THC potency/access to high-THC products, and administrative issues. Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Food & Drug Association’s role in H.B. Florida H.B.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. This article analyses media representations of medicinal cannabis in Australian medical publications. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. But bottlenecks remain to doctors prescribing the controversial treatment.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Media Contact: Eric Schudiske ( eric@s2spr.com ). What we’ve accomplished thus far is only the beginning!”.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

SpeedWeed

DECEMBER 28, 2018

Bummer: Patients Are Still Struggling for Cannabis Access. Claiming he’d never tried cannabis before in his life, Dabakis drove to Nevada, bought a cannabis-infused gummy, and then posted a live video feed of himself on social media as he ate the edible. RELATED STORY. 6 International Cannabis Strains Worth Seeking Abroad.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40